Belite Bio (BLTE) Interest Expenses (2020 - 2026)
Belite Bio (BLTE) posted quarterly Interest Expenses of -$13.2 million for Q1 2026, down 297.84% year-over-year from $6.7 million in Q1 2025, and down 212.64% quarter-over-quarter from $11.7 million in Q4 2025.
Belite Bio (BLTE) Interest Expenses (2020 - 2026) Analysis & Trends
Belite Bio's Interest Expenses history runs 7 years deep, the most recent figure standing at -$13.2 million for Q1 2026.
- In Q1 2026, Interest Expenses fell 297.84% year-over-year to -$13.2 million; the TTM figure through Mar 2026 stood at -$1.5 million (down 160.11% YoY), while the FY2025 annual figure was $359.7 million, up 31.58% from the prior year.
- Interest Expenses for Q1 2026 stood at -$13.2 million, down from $11.7 million in the prior quarter.
- The five-year high for Interest Expenses was $11.7 million in Q4 2025, with the low at -$13.2 million in Q1 2026.
- The 5-year median for Interest Expenses is $3.5 million (2023), against an average of $2.0 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 1312.1% in 2024, then jumped 378.53% in 2025.
- Belite Bio's Interest Expenses stood at $10.5 million in 2022, then slumped by 96.69% to $347000.0 in 2023, then slumped by 1312.1% to -$4.2 million in 2024, then surged by 378.53% to $11.7 million in 2025, then plunged by 212.64% to -$13.2 million in 2026.
- Business Quant data shows BLTE's Interest Expenses at -$13.2 million in Q1 2026, $11.7 million in Q4 2025, and $6.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.20 Mn |
| Mar 31, 2026 | -13.20 Mn |
| Dec 31, 2025 | 11.72 Mn |
| Dec 31, 2025 | 11.72 Mn |
| Mar 31, 2025 | 6.67 Mn |
| Mar 31, 2025 | 6.67 Mn |
| Dec 31, 2024 | -4.21 Mn |
| Dec 31, 2024 | -4.21 Mn |
| Dec 31, 2023 | 347,000.00 |
| Dec 31, 2023 | 347,000.00 |
| Dec 31, 2022 | 10.47 Mn |
| Dec 31, 2022 | 10.47 Mn |
| Dec 31, 2021 | 4.48 Mn |
| Dec 31, 2021 | 4.48 Mn |
| Dec 31, 2020 | 7.83 Mn |
| Dec 31, 2020 | 7.83 Mn |